Leadership position in generic APIs with a major focus on Antiretroviral drugs, Hepatitis C & Oncology drugs
FDF: Moved up the value chain in formulations
Synthesis (CDMO): KSMs, Intermediates & APIs to pharma innovators.
Bio: Recombinant products
Laurus Labs FY21 Annual Report Takeaways 🔬
'Capex plans are already under way to increase capacity by 1.8x by 2022'
Hit the 'retweet' & help us educate more investors.
A Thread 🧵👇
Leadership position in generic APIs with a major focus on Antiretroviral drugs, Hepatitis C & Oncology drugs
FDF: Moved up the value chain in formulations
Synthesis (CDMO): KSMs, Intermediates & APIs to pharma innovators.
Bio: Recombinant products
Robust R&D & Process chemistry skills
Compliance that meets the most stringent regulatory expectations (USFDA, etc)
Long-standing relationships | Top 10 global pharma cos. catered
750+ scientists (R&D) | 61 DMFs | 27 ANDAs | 150 patents (292 filed)
- Leaders in various high-value & high-volume APIs.
- 4 high potent manufacturing facilities: 4186 KL, increasing capacity by 24% (Strong demand)
- ARV APIs were up 70% | Onco APIs up 25% | Other APIs up 56% (higher contract manufacturing orders from 🇪🇺)
- Backwardly integrated: in house APIs
- Sales to LMIC, 🇺🇸 & 🇪🇺
- 27 ANDA filled: 9 approved+ 8 tentative.
- Capacity of 5 Billion units/yr, Increasing capacity by 100%
- Sales up 102% (growth across markets)
- Launched TLE 400 in the LMIC market
- CDMO services for global pharma with 50 active projects
- Commercial supplies ongoing for 4 products
- Sales up 35% due to client additions & increased commercialisations
During the year, acquired 73% of Richcore Lifesciences & renames it Laurus Bio.
7 manufacturing plants in Andhra Pradesh & 1 plant in Hyderabad+ a kilo lab at the Hyderabad R&D center.
Future capacities: Debottlenecking to increase by 15% by Q1FY22 & further increases over the next 3 years.
Increasing capacity by 80% in 2022 🧪
From ARV API company to API to Pharmaceutical company
Increased reactor volumes by 20 in 10 years
USFDA manufacturing sites from 1 to 5
Team strength 6 times
DMFs 5 times.
Sales up 70% YoY
33% EBITDA margin
Pat up 286% & Strong Cashflows
Strong Return ratios
4% of turnover invested in R&D
Growth Engines ->
- Formulation segment grew from 5cr to 825crs in 2 years 🤯: tender businesses
- Acquisition of Richcore: In 5yrs want to use its capabilities to do biologics at a scale
- Setting up a dedicated R&D center & manufacturing for synthesis
- Demographics: An increasingly ageing population
- Changing supply chains: 🇨🇳+1, etc
- Digital adoption across business operations
- Pressure on govt. budgets: decreasing medicine prices (generics market share to 🚀)
- CDMO adoption.
Same for the Nutraceutical/dietary supplements
& cosmeceutical segments
The company running in the right direction, let's see if the management has more surprises under their sleeves.
End of Thread.
Laurus Labs Q4FY21 results:
https://t.co/xGojyaTaeU
Laurus Labs concall takeaways \U0001f9ec
— JST Investments (@JstInvestments) April 30, 2021
Targetting $1B revenues & much more afterward (Increased capex guidance for FY22-23 from 1000crs to 1700crs)#Q4withJST #Pharma pic.twitter.com/lFcjPCOhWl
More from JST Investments
Key insights from Hikal
🧪 Lowered interest rates
🧪 Pharma: Growth in generics as well as CDMO
🧪 Crop Protection: Scaleup of a fungicide for a Japanese CDMO client
🧪 Healthy pipeline of new products: Supported by new capacities; Investing in Animal Health & Biocides verticals https://t.co/D70j9oriCa
🧪 Lowered interest rates
🧪 Pharma: Growth in generics as well as CDMO
🧪 Crop Protection: Scaleup of a fungicide for a Japanese CDMO client
🧪 Healthy pipeline of new products: Supported by new capacities; Investing in Animal Health & Biocides verticals https://t.co/D70j9oriCa
Hikal: Strong
— JST Investments (@JstInvestments) August 5, 2021
\U0001f9ea Rev up 27% YoY
\U0001f9ea 22% EBITDA margin
\U0001f9ea Pat of 50crs
\U0001f9ea Growth across both pharmaceuticals & crop protection.#Q1withJST #Pharma pic.twitter.com/8lFo68KzPe
